Orexigen Therapeutics, Inc.
DelistedCIK 1382911fmd_0P4R2YN2D327Z01VMVM6FVNJVAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2017, 31 periods
Latest annual · FY2016
Millions- Total revenues
- 34
- Gross profit
- 26
- Operating income
- (57)
- Net income
- (25)
Latest quarter · Q3 FY2017
Millions- Total revenues
- 19
- Gross profit
- 15
- Operating income
- (23)
- Net income
- (21)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2013 to FY2016
- +114.2%
- Revenue, 5 yearsFY2011 to FY2016
- +50.3%
- Net income, 5 yearsFY2011 to FY2016
- n/m
Orexigen Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2016 | FY2015 | Change | Source |
|---|---|---|---|---|
| Revenue | $33.7 million | $24.5 million | +37.8% | 10-K 2017-03-30 · proof |
| Gross profit | $25.7 million | 10-K 2017-03-30 · proof | ||
| Operating income | -$57 million | -$60.1 million | 10-K 2017-03-30 · proof | |
| Net income | -$24.5 million | -$68.7 million | 10-K 2017-03-30 · proof | |
| Cash from operating activities | -$109.7 million | -$54.5 million | 10-K 2017-03-30 · proof | |
| Free cash flow | -$110 million | -$55 million | 10-K 2017-03-30 · proof | |
| Total assets | $304.6 million | $236.3 million | +28.9% | 10-K 2017-03-30 · proof |
| Total liabilities | $247.5 million | $203 million | +22% | 10-K 2017-03-30 · proof |
| Cash and cash equivalents | $92.5 million | $155.4 million | -40.5% | 10-K 2017-03-30 · proof |
- What was Orexigen Therapeutics, Inc.'s revenue in fiscal 2016?
- Orexigen Therapeutics, Inc. reported revenue of $33.7 million for fiscal 2016 (the year ended Dec 31, 2016), against $24.5 million the year before (+37.8%). Source: the 10-K filed with the SEC on Mar 30, 2017. SEC
- What was Orexigen Therapeutics, Inc.'s gross profit in fiscal 2016?
- Orexigen Therapeutics, Inc. reported gross profit of $25.7 million for fiscal 2016 (the year ended Dec 31, 2016). Source: the 10-K filed with the SEC on Mar 30, 2017. SEC
- What was Orexigen Therapeutics, Inc.'s operating income in fiscal 2016?
- Orexigen Therapeutics, Inc. reported operating income of -$57 million for fiscal 2016 (the year ended Dec 31, 2016), against -$60.1 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2017. SEC
- What was Orexigen Therapeutics, Inc.'s net income in fiscal 2016?
- Orexigen Therapeutics, Inc. reported net income of -$24.5 million for fiscal 2016 (the year ended Dec 31, 2016), against -$68.7 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2017. SEC
- What was Orexigen Therapeutics, Inc.'s cash from operating activities in fiscal 2016?
- Orexigen Therapeutics, Inc. reported cash from operating activities of -$109.7 million for fiscal 2016 (the year ended Dec 31, 2016), against -$54.5 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2017. SEC
- What was Orexigen Therapeutics, Inc.'s free cash flow in fiscal 2016?
- Orexigen Therapeutics, Inc. reported free cash flow of -$110 million for fiscal 2016 (the year ended Dec 31, 2016), against -$55 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2017. SEC
- What are Orexigen Therapeutics, Inc.'s total assets?
- As of Dec 31, 2016, Orexigen Therapeutics, Inc. reported total assets of $304.6 million, against $236.3 million a year earlier (+28.9%). Source: the 10-K filed with the SEC on Mar 30, 2017. SEC
- What are Orexigen Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2016, Orexigen Therapeutics, Inc. reported total liabilities of $247.5 million, against $203 million a year earlier (+22%). Source: the 10-K filed with the SEC on Mar 30, 2017. SEC
- What are Orexigen Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2016, Orexigen Therapeutics, Inc. reported cash and cash equivalents of $92.5 million, against $155.4 million a year earlier (-40.5%). Source: the 10-K filed with the SEC on Mar 30, 2017. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1382911&period_type=annual&limit=5"Information only, not investment advice.